Corner Therapeutics Debuts with Data Presentation on its Dendritic Cell Hyperactivation Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Excerpt from the Press Release:

WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost memory T cell responses to disease, debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12, 2022 in Boston, Massachusetts.

Corner has developed a new therapeutic modality—DC hyperactivators—which induce the production of polyclonal populations of long-lived memory T cells that exhibit durable protective immunity to cancer. Using proprietary chemicals and formulations, Corner’s DC hyperactivators mimic the molecular signals dendritic cells naturally experience during virulent infections.

The resulting hyperactive dendritic cells exhibit migratory capacity that is 30 times greater than what can be elicited by current FDA-approved immunostimulants. This enhanced migration enables far more antigen to be delivered to lymph nodes and a diversification of the resulting T cell responses that mediate protective immunity. DC hyperactivators also induce production of cytokines from dendritic cells that Toll-like Receptor (TLR) and other known immunostimulants cannot elicit, such as the key memory T cell inducing cytokine interleukin-1 (IL-1). The combination of these activities enables Corner’s DC hyperactivators to stimulate human memory T cells 1000 times more effectively than TLR-based dendritic cell stimuli.

Click the button below to read the entire Press Release:

Continue Reading The Press Release